The gigantic offer for AstraZeneca by Pfizer is, or should be, a bellwether event. It has nothing obvious to recommend it, except that the US pharmaceuticals group should save on its tax liabilities. That the UK government – allegedly opposed to unfair tax competition – should have made this possible is bad enough. That it should have done so at the expense of one of the UK’s most important companies is worse.
輝瑞(Pfizer)擬斥巨資收購(gòu)阿斯利康(AstraZeneca)是（或者應(yīng)該是）一個(gè)風(fēng)向標(biāo)事件。這沒(méi)啥好說(shuō)的，除了這家美國(guó)制藥集團(tuán)居然避稅以外。據(jù)說(shuō)反對(duì)不公平稅收競(jìng)爭(zhēng)的英國(guó)政府竟然讓輝瑞避稅成為可能，這已經(jīng)夠糟糕的了，而更糟糕的是，它這么做竟然是以英國(guó)最重要的公司之一為代價(jià)的。
您已閱讀8%（553字），剩余92%（6086字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。